Clinical trials: Paramyxoviridae Infections
Asthma, Pertussis
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
The main objective is to estimate the annual symptomatic incidence of Bordetella pertussis and RSV infections in patients aged 18 years and over with asthma, which will be identified by PCR, for Bordetella pertussis and by PCR…
- Conditions
- Asthma, Pertussis, RSV Infection
- Trial name
- PRIPASCO (NCT06286007)
- Testing
- PCR
- Where
- Spain
- Volunteers
- 784 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Respiratory Syncytial Virus Infections
Music Therapy With Intubated and Sedated Pediatric Patients
The study is a randomized controlled trial of pediatric patients ages birth to two years of age who are mechanically ventilated and sedated as a result of a respiratory virus.
- Trial name
- NCT03629145
- Testing
- Live Music Therapy, Recorded Music Therapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Children's Healthcare of Atlanta
Measles
Clinical Diagnostic Performance Evaluation of a Measles Rapid Test in Senegal
The goal of this study is to measure the accuracy of a new measles rapid test when used in clinical health centres in several regions of Senegal.
- Trial name
- NCT05860920
- Testing
- Measles rapid diagnostic test
- Where
- 6 sites in Senegal
- Volunteers
- 254 people
- Sponsor
- Institut Pasteur de Dakar
RSV Infection
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
Gates MRI-RSM01-101 was a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, occurrence of Anti-drug antibody (ADA), and assessment of…
- Trial name
- NCT05118386
- Testing
- RSM01
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Respiratory Syncytial Virus Infections
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
- Trial name
- NCT01968083
- Testing
- RSV cps2 Vaccine
- Where
- 5 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RSV Infection
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
- Trial name
- NCT03755778
- Testing
- EDP-938, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus Immunization
Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different liponanaoparticle (LNP) formulations of modified ribonucleic acid (mRNA) vaccines using the RSV pre-F antigen in healthy participants 18 to 49…
- Trial name
- NCT07071558
- Testing
- RSV vaccine formulation 1 dose, RSV vaccine formulation 2 dose, RSV vaccine formulation 3 dose
- Where
- 6 sites in Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi
Rubella, Measles
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \&…
- Conditions
- Rubella, Measles, Mumps
- Trial name
- NCT01702428
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 90 sites in United States, Estonia and 4 more
- Volunteers
- 5,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
MEASLES DISEASE
Unravelling the Measles Paradox in Children
Measles is caused by measles virus (MeV). The disease is associated with lymphopenia and immune suppression, which is an important cause of measles-associated morbidity and mortality.
- Trial name
- MISIA-k (NCT06923631)
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Parainfluenza Infection
DAS181 in Patients With Parainfluenza
Background: Parainfluenza is a virus that can cause infections in people. Most people infected with this virus have mild symptoms including fever, cough, red eyes, or runny nose (a common cold).
- Trial name
- NCT01441024
- Testing
- DAS181
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Measles, Mumps
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older. The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose…
- Conditions
- Measles, Mumps, Rubella, Adverse Event Following Immunisation
- Trial name
- NCT03160820
- Testing
- Measles, mumps and rubella Combined Vaccine, Live
- Where
- 4 sites in China
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Bronchiolitis, Acute Bronchiolitis
Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital
The purpose of this observational study is to identify the risk factors that make bronchiolitis more severe in infants and toddlers.
- Conditions
- Bronchiolitis, Acute Bronchiolitis, Respiratory Syncytial Virus Infection
- Trial name
- NCT07505420
- Volunteers
- 65 people
- Sponsor
- Assiut University
Measles, Mumps
ProQuad Dose Selection Study (V221-011)(COMPLETED)
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00986232
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV
- Volunteers
- 1,551 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infections
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels of JNJ-53718678 in children greater than or…
- Trial name
- NCT03656510
- Testing
- JNJ-53718678
- Where
- 169 sites in United States, Argentina and 20 more
- Volunteers
- 246 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Syncytial Virus Infections
The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan
RSV has a global healthcare burden and vaccine in the main preventive measure. There are no recent published studies that have evaluated the burden of RSV infections in the Middle East in term of incidence at a national level…
- Trial name
- RSV-JO (NCT05562817)
- Where
- Jordan
- Volunteers
- 1,200 people
- Sponsor
- MENA Center for Research & Development and Internship
Measles
Early Waning of Maternal Measles and Meningitis C Antibodies
Maternal antibodies (measles and meningitis C) may wane in the first six months after birth. Geometric mean titers(GMTs) of measles and meningitis C. Follow-up on 0 month, 3rd month,5th month and 7th month after birth.
- Trial name
- EWMM (NCT02219061)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangzhou Center for Disease Control and Prevention
Stem Cell Transplantation
Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
Introduction. Chronic graft-versus-host-disease (GVHD) is the main late noninfectious complication after allogeneic hematopoietic stem cell transplantation (HSCT) that can affect several organs.
- Trial name
- ALLOVIRO (NCT03684083)
- Testing
- bronchial biopsies
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Measles, Rubella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Measles, Rubella, Mumps, Varicella
- Trial name
- NCT00127010
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 48 sites in Belgium, Germany and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Infection
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine (RSV 6120/∆NS2/1030s) in RSV-seropositive children…
- Trial name
- NCT03387137
- Testing
- RSV 6120/∆NS2/1030s
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infection
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
The primary objectives of the study were: To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus.
- Trial name
- VAD00001 (NCT04491877)
- Testing
- RSV vaccine formulation 1, RSV vaccine formulation 2
- Where
- 29 sites in United States, Chile and 1 more
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company